Lord Hunt of Kings Heath – 2015 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2015-11-19.
To ask Her Majesty’s Government what assessment they have made of the potential savings to the budgets of Clinical Commissioning Groups from the use of the drug bevacizumab in the treatment of age-related macular degeneration instead of ranibizumab.
Lord Prior of Brampton
No assessment of the potential savings to clinical commissioning group budgets has been made as there are two other effective licensed treatments for wet age-related macular degeneration recommended by the National Institute for Health and Care Excellence.
